Watson Challenges Cancer

The IBM supercomputer, famous for its game show performance, will aid in cloud-based analyses of genomic data.  

By | March 20, 2014

WIKIMEDIA, CLOCKREADYIBM’s Watson, a supercomputer and one of the most famous “Jeopardy!” champions, will now be deployed in the service of oncologists. The New York Genome Center and IBM this week (March 19) announced a partnership through which Watson will analyze genomic data, with the goal of developing personalized medicine for cancer patients.

“We’re hoping Watson’s learning model can find associations faster than we can and they’ll be able to tune the sets of drugs to at least prioritize and give doctors the ability to drill down so that they can make better determinations of what to try,” Toby Bloom, the deputy scientific director for informatics at the New York Genome Center, told Forbes.

At the outset, Watson will compare genomic data from tumors and non-tumorous tissue from a small group of patients with glioblastoma, a notoriously difficult-to-treat brain cancer. “Time definitely is not on your side when you have glioblastoma and that’s where Watson comes in,” Robert Darnell, the New York Genome Center’s president, CEO, and scientific director, told reporters. John Kelly, a senior vice president and director of IBM Research, told the Associated Press that “Watson can do in seconds what would take people years. And we can get it down to a really personal level.”

According to Forbes, if the initial glioblastoma project is a success, the effort will be scaled up to include more patients.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech